WallStreetZenWallStreetZen

NASDAQ: KALA
Kala Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KALA

Based on 3 analysts offering 12 month price targets for Kala Bio Inc

Min Forecast
$12.00-34.5%
Avg Forecast
$25.00+36.46%
Max Forecast
$33.00+80.13%

Should I buy or sell KALA stock?

Based on 3 analysts offering ratings for Kala Bio Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KALA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates KALA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their KALA stock forecasts and price targets.

KALA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-11
lockedlocked$00.00+00.00%2025-09-08
lockedlocked$00.00+00.00%2025-05-23

1 of 1

Forecast return on equity

Is KALA forecast to generate an efficient return?

Company
-893.03%
Industry
29.98%
Market
-49.74%
KALA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KALA forecast to generate an efficient return on assets?

Company
-105.64%
Industry
14.58%
KALA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KALA earnings per share forecast

What is KALA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$5.33
Avg 2 year Forecast
-$4.06
Avg 3 year Forecast
-$6.72

KALA revenue forecast

What is KALA's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$96.5M
Avg 2 year Forecast
$228.6M

KALA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
KALA$18.32$25.00+36.46%Buy
CTOR$1.86N/AN/A
CRDL$1.08$9.00+733.33%Buy
ASRT$0.84$3.00+257.14%Buy
INCR$1.57N/AN/A
View Top Pharmaceutical Stocks

Kala Bio Stock Forecast FAQ

Is Kala Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KALA) stock is to Buy KALA stock.

Out of 3 analysts, 0 (0%) are recommending KALA as a Strong Buy, 3 (100%) are recommending KALA as a Buy, 0 (0%) are recommending KALA as a Hold, 0 (0%) are recommending KALA as a Sell, and 0 (0%) are recommending KALA as a Strong Sell.

If you're new to stock investing, here's how to buy Kala Bio stock.

What is KALA's earnings growth forecast for 2025-2027?

(NASDAQ: KALA) Kala Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 24.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Kala Bio's earnings in 2025 is -$35,651,000.On average, 4 Wall Street analysts forecast KALA's earnings for 2025 to be -$34,375,150, with the lowest KALA earnings forecast at -$38,456,292, and the highest KALA earnings forecast at -$31,036,034. On average, 4 Wall Street analysts forecast KALA's earnings for 2026 to be -$26,164,474, with the lowest KALA earnings forecast at -$31,423,178, and the highest KALA earnings forecast at -$18,002,190.

In 2027, KALA is forecast to generate -$43,360,115 in earnings, with the lowest earnings forecast at -$43,360,115 and the highest earnings forecast at -$43,360,115.

What is KALA's revenue growth forecast for 2029-2030?

(NASDAQ: KALA) Kala Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.

Kala Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast KALA's revenue for 2029 to be $622,398,311, with the lowest KALA revenue forecast at $622,398,311, and the highest KALA revenue forecast at $622,398,311.

In 2030, KALA is forecast to generate $1,474,953,659 in revenue, with the lowest revenue forecast at $1,474,953,659 and the highest revenue forecast at $1,474,953,659.

What is KALA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KALA) forecast ROA is -105.64%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 14.58%.

What is KALA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KALA price target, the average KALA price target is $25.00, with the highest KALA stock price forecast at $33.00 and the lowest KALA stock price forecast at $12.00.

On average, Wall Street analysts predict that Kala Bio's share price could reach $25.00 by Sep 11, 2026. The average Kala Bio stock price prediction forecasts a potential upside of 36.46% from the current KALA share price of $18.32.

What is KALA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KALA) Kala Bio's current Earnings Per Share (EPS) is -$7.97. On average, analysts forecast that KALA's EPS will be -$5.33 for 2025, with the lowest EPS forecast at -$5.96, and the highest EPS forecast at -$4.81. On average, analysts forecast that KALA's EPS will be -$4.06 for 2026, with the lowest EPS forecast at -$4.87, and the highest EPS forecast at -$2.79. In 2027, KALA's EPS is forecast to hit -$6.72 (min: -$6.72, max: -$6.72).

What is KALA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KALA) forecast ROE is -893.03%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.